Jerini is a leader in the systematic discovery and development of peptidomimetic and small molecule drugs derived from peptides.The company's Peptides-to-Drugs (P2D) technology platform facilitates the development of both peptidomimetic drugs (injectable), and small molecules (orally available) depending on the disease indication. Systematic program diversification balances the inherent risks and benefits associated with drug development and ensures significant opportunities for Jerini's future growth and increased company value.